Sze Chuen Cesar Wong1, Thomas Chi Chuen Au2,3, Sammy Chung Sum Chan4, Lawrence Po Wah Ng5, Hin Fung Tsang1. 1. Department of Health Technology and Informatics, Faculty of Health and Social Sciences, Hong Kong Polytechnic University. 2. State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Chinese University of Hong Kong. 3. Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, Chinese University of Hong Kong. 4. Department of Obstetrics & Gynaecology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China. 5. Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, China.
Abstract
Background: Human papillomavirus (HPV) is a known causative factor in the etiology of cervical cancer. Methods: HPV DNA genotyping was performed in menstrual blood (MB) collected in napkins from patients with cervical intraepithelial neoplasia (CIN), HPV infection and sexually active apparently normal subjects. In the same patient cohort, MB TAP1 I333V and TAP1 D637G gene polymorphisms were examined. Results: The sensitivity, specificity, and positive and negative predictive values of HPV DNA in the detection of CIN or HPV infection were 83% (223 of 268), 98% (131 of 134), 99% (223 of 226), and 74% (131 of 176), respectively. Moreover, HPV DNA was found in 24% (28/118) patients who had loop electrosurgical excision procedure treatment and 0% (0/76) HPV infected or CIN1 patient with proven recovery. On the other hand, the risk of developing high-grade CIN was significantly reduced for AG and GG genotypes compared with AA genotype and for carriers with a G allele compared with those with an A allele for both polymorphisms. Conclusions: MB HPV DNA is a potential noninvasive marker for screening and monitoring of squamous intraepithelial lesion. Together with TAP1 I333V and TAP1 D637G gene polymorphisms, the combined test may be useful for stratifying high-risk patients for better follow-up strategies.
Background: Human papillomavirus (HPV) is a known causative factor in the etiology of cervical cancer. Methods:HPV DNA genotyping was performed in menstrual blood (MB) collected in napkins from patients with cervical intraepithelial neoplasia (CIN), HPV infection and sexually active apparently normal subjects. In the same patient cohort, MB TAP1I333V and TAP1D637G gene polymorphisms were examined. Results: The sensitivity, specificity, and positive and negative predictive values of HPV DNA in the detection of CIN or HPV infection were 83% (223 of 268), 98% (131 of 134), 99% (223 of 226), and 74% (131 of 176), respectively. Moreover, HPV DNA was found in 24% (28/118) patients who had loop electrosurgical excision procedure treatment and 0% (0/76) HPV infected or CIN1 patient with proven recovery. On the other hand, the risk of developing high-grade CIN was significantly reduced for AG and GG genotypes compared with AA genotype and for carriers with a G allele compared with those with an A allele for both polymorphisms. Conclusions: MB HPV DNA is a potential noninvasive marker for screening and monitoring of squamous intraepithelial lesion. Together with TAP1I333V and TAP1D637G gene polymorphisms, the combined test may be useful for stratifying high-risk patients for better follow-up strategies.